Table 2.
ID# | Rx Dose (Gy) |
Maximum Cord Dose (Gy) |
Age at SRS (weeks) |
Follow-up (weeks) |
Latency (weeks) |
---|---|---|---|---|---|
1 | 14 | 14.9 | 95 | 41 | NA* |
2 | 14 | 14.8 | 94 | 39 | NA* |
3 | 16 | 17.3 | 99 | 52 | NA* |
4 | 16 | 17.3 | 99 | 52 | NA* |
5 | 16 | 16.7 | 99 | 53 | NA* |
6 | 18 | 19.0 | 96 | 48 | NA* |
7 | 18 | 19.0 | 94 | 48 | NA* |
8 | 18 | 19.0 | 100 | 29 | 14 |
9 | 18 | 18.8 | 100 | 36 | 24 |
10 | 18 | 19.2 | 99 | 53 | NA* |
11 | 20 | 21.1 | 96 | 18 | 16 |
12 | 20 | 21.3 | 97 | 53 | NA* |
13 | 20 | 21.3 | 101 | 14 | 13 |
14 | 20 | 21.1 | 101 | 22 | 20 |
15 | 20 | 21.1 | 98 | 18 | 16 |
16 | 22 | 23.2 | 96 | 20 | 18 |
17 | 22 | 23.2 | 97 | 16 | 16 |
18 | 22 | 23.7 | 97 | 14 | 13 |
19 | 22 | 23.2 | 100 | 17 | 17 |
20 | 22 | 23.5 | 97 | 14 | 13 |
21 | 24 | 25.3 | 97 | 17 | 9 |
22 | 24 | 25.1 | 97 | 19 | 19 |
23 | 24 | 25.9 | 99 | 16 | 15 |
No motor neurologic deficits were observed in stated follow-up period.